NCT01786343View on ClinicalTrials.gov

Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 5, 2013

Primary Completion Date

May 6, 2019

Study Completion Date

May 6, 2019

Conditions
Leukemia
Interventions
DRUG

Decitabine

20 mg/m2 by vein daily for either 5 or 10 days.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01786343 - Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter